AD-35

AD-35 is an orally active anti-Alzheimer's disease (AD) agent with moderate AChE inhibitory activity and metal ion chelating ability. AD-35 exhibits IC50 values for AChE and BuChE of 793 nM and 31428 nM, respectively. AD-35 can form chelates with Cu²⁺ and Fe³⁺, but its chelating ability for Zn²⁺ is relatively weak. AD-35 can inhibit Aβ aggregation and disassemble the formed Aβ aggregates, and inhibit Aβ-induced ERK phosphorylation. AD-35 inhibits neuroinflammation in AD rat models and demonstrates a strong effect in improving cognitive function[1].

Product Specifications

CAS Number

[1531586-64-7]

UNSPSC

12352005

Target

Amyloid-β; Cholinesterase (ChE) ; ERK; Interleukin Related; TNF Receptor

Related Pathways

Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Neuronal Signaling; Stem Cell/Wnt

Field of Research

Neurological Disease

Smiles

O=C(N(CCC1CCN(CC2=CC=CC=N2)CC1)C34CC4)C(C3=C5)=CC6=C5OCO6.OP(O)(O)=O

Molecular Formula

C24H30N3O7P

Molecular Weight

503.48

References & Citations

[1]Li L, et al. Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-α and IL-1β in an Aβ25-35-induced Rat Model of Alzheimer's Disease. J Alzheimers Dis. 2017;56 (4) :1403-1417.